Skip to content

ESMO Congress 2026

October 23–27, 2026 · Madrid · 2854 items

← Floor

#LCSM

★★★

10 people · 26 posts

Heat trend for this story

Heat now 4·Peak in the comparable set 4 (Oct 24 18:00)·Change over 24h in the comparable set –·Participants now 6

Participants counted6
0246
Heat over time
0246Oct24Oct24Oct24Oct24
Deep dive

First, the boundary of evidence: none of the background references provided relate to oncology—the acronym LCSM there stands for laser confocal scanning microscopy [1][2][3][4] or Latent Change Score Models [5][6], only coincidentally matching the lung cancer social media hashtag #LCSM. Accordingly, the published Phase III evidence that would establish the lung cancer ADC / TOP1 payload class has no corresponding literature within the given materials; the specific trials and data remain to be confirmed, and this piece makes no judgment on class maturity beyond the materials.

The key meeting-level information: ESMO26 is held in Madrid, Oct 23–27, and the live posts cluster around the pre-meeting days and opening day. @ADesaiMD posted a ranked list of his top 7 thoracic picks, stating that 5 of these phase 3s have already announced positive toplines, and that ESMO is where we finally see effect sizes—the question each one answers will be revealed here; the names of those seven trials and any efficacy figures are not disclosed. @GlopesMd separately listed the top ten #LCSM presentations, and @OncLive ran and published a readers' poll on the most anticipated lung cancer abstracts. Running parallel to the “waiting for effect sizes” thread is a second line of discussion: @MeDucationai relayed the mechanistic question raised by @lungoncdoc—if resistance lives in the TOP1 payload, a new antibody target may not rescue response, and most of the lung ADCs in play carry TOP1 payloads.

Relative to existing knowledge, this meeting could advance two steps: first, refining the already-announced positive toplines from binary outcomes into comparable effect sizes, clarifying the specific clinical question each phase 3 answers; second, shifting the ADC discussion from “switching antibody targets” toward “whether resistance resides in the payload or the antibody,” pre-setting an interpretive frame for the upcoming readouts. Because the background materials contain no pivotal trial data for same-class ADCs, this step can only be described at the level of the posts themselves, and formal benchmarking against prior phase 3s remains to be confirmed.

The limitation: at the time of posting the congress had not yet opened or had just opened; key trial names, populations, and primary endpoint values are all undisclosed, and social media commentary represents pre-meeting expectations rather than peer-reviewed data. How much weight the two discussion lines ultimately carry depends on the effect sizes and ADC data formally presented at ESMO26.

References
  1. 1.Ecotoxicity and genotoxicity of polystyrene microplastics on higher plant Vicia faba · Environ Pollut 2019
  2. 2.Impact of polystyrene nanoplastics (PSNPs) on seed germination and seedling growth of wheat (Triticum aestivum L.) · J Hazard Mater 2020
  3. 3.The Semen pH Affects Sperm Motility and Capacitation · PLoS One 2015
  4. 4.Structural stability and release profiles of proteins from core-shell poly (DL-lactide) ultrafine fibers prepared by emulsion electrospinning · J Biomed Mater Res A 2008
  5. 5.Teacher's Corner: Latent Curve Models and Latent Change Score Models Estimated in R · Struct Equ Modeling 2012
  6. 6.White matter and memory in healthy adults: Coupled changes over two years · Neuroimage 2016
Floor
  1. gilberto lopes

    Getting ready for @myesmo #ESMO26?

    引用@

    🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁 The abstracts our faculty picked as must-know from Madrid 👇 1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC 2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC 3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib 4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI 5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC 6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50% 7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC 8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months 9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI 🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC #lcsm #OncoAlert #MedTwitter Pinging our OncoAlert Lung Cancer Faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran

    Same topic #LCSM · 10 people1342 views24 likes14 reposts0 replies
  9. Hidehito HORINOUCHI

    🆙#ESMO26 #LCSM Multidisciplinary Sesssion

    引用@

    Delighted to join Dr Yi-Chen Zhang, Dr Calvo de Juan and Prof Yi-Long Wu in discussing the role of local therapy in non-small cell lung cancer at #ESMO26 in #Madrid this afternoon. Superb case discussion and fascinating insights into novel approaches such as the role of ctDNA In selection and monitoring of patients. @myESMO @CancerInstIRE @tcddublin @TrinityMed1

    Same topic #LCSM · 10 people118 views3 likes3 reposts0 replies
  23. Hidehito HORINOUCHI

    🆙#ESMO26 #LCSM Multidisciplinary Sesssion

    引用@

    Delighted to join Dr Yi-Chen Zhang, Dr Calvo de Juan and Prof Yi-Long Wu in discussing the role of local therapy in non-small cell lung cancer at #ESMO26 in #Madrid this afternoon. Superb case discussion and fascinating insights into novel approaches such as the role of ctDNA In selection and monitoring of patients. @myESMO @CancerInstIRE @tcddublin @TrinityMed1

    Same topic #LCSM · 10 people4 views0 likes0 reposts0 replies
  24. Hidehito HORINOUCHI

    🆙#ESMO26 #LCSM Multidisciplinary Sesssion

    引用@

    Delighted to join Dr Yi-Chen Zhang, Dr Calvo de Juan and Prof Yi-Long Wu in discussing the role of local therapy in non-small cell lung cancer at #ESMO26 in #Madrid this afternoon. Superb case discussion and fascinating insights into novel approaches such as the role of ctDNA In selection and monitoring of patients. @myESMO @CancerInstIRE @tcddublin @TrinityMed1

    Same topic #LCSM · 10 people16 views0 likes0 reposts0 replies
  28. MeDucation

    @lungoncdoc is raising the question lung oncologists need before Madrid: if resistance lives in the TOP1 payload, a new antibody target may not rescue response, and most of the lun

    引用@

    Important implications for lung cancer, too. We’re behind breast cancer in understanding optimal ADC sequencing, but emerging data raise an important concern: switching targets may not overcome resistance when the payload remains the same... #ESMO26

    Same topic #LCSM · 10 people39 views0 likes0 reposts0 replies
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org